Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update

GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France

GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

GenSight Biologics Announces its 2021 Financial Calendar